|
|
||||||||
RECEPTORS AND SIGNAL TRANSDUCTION

1Cardiovascular Disease Research Program, 2Neuroscience of Drug Abuse Research Program, Julius L. Chambers Biomedical/Biotechnology Research Institute, North Carolina Central University, Durham; and 3Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, Research Triangle Park; and 4Hypertension, Vascular Diseases Center and Department of Physiology, and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Submitted 25 July 2006 ; accepted in final form 22 January 2007
| ABSTRACT |
|---|
|
|
|---|
50%. Similar reductions were observed with repeated applications of 10 mM Ca2+, 1 and 10 µM NPS R-467, or 50 and 100 µM Gd3+, indicating desensitization of the response. Furthermore, Ca2+ mobilization increased phosphorylated protein kinase C (PKC)
levels in the cells. However, the PKC activator, phorbol myristate acetate did not inhibit CaR-mediated Ca2+ signaling. Rather, a spectrum of PKC inhibitors partially reduced peak responses to Cae2+. Treatment of cells with 100 nM PMA for 24 h, to downregulate PKC, reduced [Ca2+]i transients by 49.9 ± 5.2% (at 1 mM Ca2+) and 40.5 ± 6.5% (at 2 mM Ca2+), compared with controls. The findings suggest involvement of PKC in the pathway for Ca2+ mobilization following CaR activation. desensitization; protein kinase C
-aminobutyric acid type B receptors (GABABR) (29), putative pheromone receptors (50) and putative taste receptors (23). The receptor has a large NH2-terminal extracellular domain with multiple glycosylation sites, seven transmembrane-spanning domains, and a COOH-terminal intracellular tail with phosphorylation sites (14, 49). These domains have distinct properties that confer ligand binding and G protein-coupling specificity. Molecular evidence for the existence of the CaR was initially provided by Brown et al. (6), who demonstrated the presence of a novel protein (with homology to the mGluR) in bovine parathyroid cells. Since then, the presence of similar receptors has been reported in kidney (1, 46), keratinocytes (4, 37), brain (49), intestinal epithelia (11, 16), and bone (40). It is well established that the CaR provides the primary mechanism for [Ca2+]e-mediated regulation of the release of parathyroid hormone as a result of parathyroid cells sensing small changes in serum [Ca2+]e (7), a process similar to the mechanism involved in catecholamine- and small peptide-induced G-protein coupled activation of cell surface receptors (22). However, the function of this receptor in other tissues has not been well characterized.
In earlier studies, we demonstrated that the dorsal root ganglion (DRG), which houses cell bodies of sensory nerves that send afferent processes to tissues, such as the perivascular adventitia, expresses the message encoding the CaR (8). We later showed that a protein immunoreactive with an antibody raised against the human parathyroid CaR is present in a subpopulation of periadventitial nerves (55). Furthermore, we determined that the 5' untranslated region of the mRNA that gives rise to the DRG CaR cDNA is significantly different from those of the parathyroid and kidney, suggesting that this protein is a product of the expression of alternate exons. These findings and physiological studies led us to hypothesize that activation of the perivascular CaR results in the release of a hyperpolarizing vasodilator compound, which relaxes adjacent smooth muscle cells (8, 9, 27). We have since cloned the rat DRG CaR cDNA into an EGFP vector (EGFP-N3) and functionally expressed it, in frame, as a fusion to the NH2-terminus (57). We also showed that the COOH-terminal amino acid sequence is considerably different from that of the CaR found in human parathyroid gland (57). This difference probably determines the behavior of the rat DRG CaR, including desensitization and coupling of G proteins in the signal transduction pathway. The present study was undertaken to further characterize this novel CaR because of its potential importance in the control of sensory nerve and vascular function (35, 55, 56) as well as its potential as a therapeutic target.
| MATERIALS AND METHODS |
|---|
|
|
|---|
(Ser657) antibody was from Santa Cruz Biotechnology (Santa Cruz, CA), NPS R-467, NPS S-467, and CaR monoclonal antibody, raised against a synthetic peptide corresponding to residue 214235 of the extracellular domain of the human parathyroid CaR, were gifts from NPS Pharmaceuticals (Salt Lake City, UT). This antibody is now available commercially as MA1934 (Affinity Bioreagents, Golden, CO). All other chemicals used were of the purest grade available commercially. Stable transfection of HEK293 cells expressing EGFP or CaR.EGFP. In-frame fusion of the cDNA encoding full-length DRG CaR with EGFP was carried out as previously described (57). HEK293 cells were grown as monolayer cultures in DMEM, supplemented with 10% FBS and penicillin/streptomycin (100 U ml1·100 µg·ml1) at 37°C in 5% CO2, and transfected with the CaR cDNA-EGFP fusion construct using Lipofectamine 2000. Briefly, a mixture of 4 µg plasmid DNA and Lipofectamine 2000 in OPTI-MEM I reduced serum medium was added to cells grown in DMEM (plus 10% FBS, but without penicillin/streptomycin) in 100 mm dishes for 24 h. After incubating at 37°C in 5% CO2 for 4 h, the medium was replaced with DMEM, supplemented with 10% FBS and penicillin/streptomycin (100 U ml1/100 µg·ml1) and cells grown for 48 h to allow expression of the CaR.EGFP fusion protein. Cells were then trypsinized and replated in fresh medium and the incubation continued overnight, followed by addition of G-418 sulfate (600 µg/ml). The medium was changed every 24 days for 3 wk to allow colonies of resistant cells to grow. Individual colonies were then selected and grown to generate cell lines (HEK-CaR.EGFP) stably expressing the CaR.EGFP fusion protein. HEK293 cells transfected with EGFP vector (HEK-EGFP) served as control. Cells were separated by fluorescence-activated cell sorting (FACS) to obtain populations uniformly showing green fluorescence and assayed for gene expression. A homogenous population of HEK293 cells, stably expressing the CaR.EGFP fusion protein were grown on 25 mm glass coverslips for 48 h and analyzed. For the present study, a population of cells in passages 15 (P1P5) was used. Cells collected after sorting are designated as P0.
Microfluorimetric measurement of [Ca2+]i in HEK-CaR.EGFP cells. [Ca2+]i was measured in cells loaded with the fluorescent indicator, fura 2. Briefly, cells were washed twice with HBSS and loaded for 30 min with 5 µM fura 2-AM, dissolved in HBSS supplemented with Pluronic F-127 (0.02%). After excess dye was washed off, the coverslip was mounted in an Attofluor cell chamber in physiological salt solution composed of (in mM) 150 NaCl, 5.4 KCl, 1.2 MgSO4, 1.2 7H2O; 1.2 NaH2PO4, 6.0 NaHCO3, 0.25 CaCl2, 5.5 glucose, and 20 HEPES, pH 7.4, and placed on the stage of an Axiovert 100S inverted microscope equipped with a Zeiss Fluar x40 fluorescence oil-immersion objective. In experiments with gadolinium (Gd3+) chloride, NaH2PO4, and NaHCO3 were omitted from the solution. An imaging system (Dual-wavelength Fluorescence Imaging System; PTI, Birmingham, NJ) was used to measure [Ca2+]i. Cells, loaded with fura 2, were excited at 340 nm and 380 nm with a xenon light source (75 Watt Xe Compact Arc Lamp) and emission at 510 nm was captured by an IC-300 intensified charge-coupled device camera. The images were transmitted to a computer and processed using the ImageMaster Pro Ratio Fluorescence Imaging software, with a macro based on the concentration equation of Grynkiewicz et al. (20) to transform the data from ratio into Ca2+ concentrations. The [Ca2+]i data are reported as emission ratios (F340/F380) or nM [Ca2+]i. In all experiments, 2030 cells from a single field were analyzed and the means calculated, and applications of 10 µM ionomycin and 20 mM EGTA followed Ca2+ response determinations to obtain the maximum possible level (Rmax) and the minimum level (Rmin) in Cai2+, respectively.
RT-PCR analysis of RNA extracted from control and transfected HEK293 cells. To demonstrate the presence of the CaR message in HEK-CaR.EGFP cells, total cellular RNA was extracted from HEK293, HEK-EGFP, and HEK-CaR.EGFP cells that had been grown in T75 flasks for 48 h. Total cellular RNA was amplified by RT-PCR with the same primers used to amplify the full-length CaR cDNA for cloning into the EGFP vector. The PCR products were subjected to restriction analysis using PstI and EcoRI endonucleases and the fragments visualized by ethidium bromide staining, after separation by electrophoresis on 1% agarose gel.
Western blot analysis of proteins extracted from transfected HEK293 cells. Cells were grown in 100 mm dishes for 48 h and total membrane protein extracted by homogenization in ice-cold solution of 10 mM Tris (pH 7.5), 0.25 M sucrose, and 3 mM MgCl2 with freshly added protease inhibitor cocktail (1 µM leupeptin, 1 mM dithiothreitol, 1 µM pepstatin, 5 mM pefabloc, 1 µg/ml bestatin, and 7 µg/ml calpain inhibitor II). The homogenate was then passed through a 22-gauge needle, centrifuged at 800 g for 10 min, and the supernatant from this step centrifuged at 100,000 g for 2 h. The resultant pellet was then dissolved in Tris buffer (pH 7.5), with 1% Triton X-100 and freshly added protease inhibitor cocktail as above, size separated using 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane. The membrane was then blotted with the CaR antibody (19, 38, 39), incubated with horseradish peroxidase-conjugated anti-mouse IgG, and visualized using the ECL method. Membrane proteins were also prepared from HEK-CaR.EGFP cells stimulated with 1 mM Ca2+ for specified time periods and analyzed for phosphorylated-PKC (p-PKC) with anti-p-PKC antibody.
Statistical analysis. Data were analyzed using SigmaPlot 9.0 and SigmaStat 3.1 computer software programs (SYSTAT, Port Richmond, CA). Comparisons between treatment groups were made by ANOVA. Differences having P < 0.05 were considered significant.
| RESULTS |
|---|
|
|
|---|
|
|
|
|
|
|
|
|
, a conventional PKC isoform, following stimulation of the CaR. This isoform has been shown to co-localize with the CaR in lipid rafts in bovine parathyroid cells (30, 52), and is abundantly expressed, endogenously in HEK293 cells (51). We determined Cae2+-induced association of phosphorylated PKC
(pPKC
) with membrane proteins over time as well as the effects of pharmacological manipulations of PKC activity on Cai2+ mobilization. Increasing Cae2+ from 0.25 to 1.25 mM increased Cai2+ mobilization and resulted in increased pPKC
levels associated with cell membranes (Fig. 9). However, as shown in Fig. 10A, acute activation of PKC by 100 nM phorbol myristate acetate (PMA) had no effect on CaR-mediated [Ca2+]i signals. After chronic stimulation of cells with 100 nM PMA for 24 h, a procedure expected to cause downregulation of PKC activity, there was a partial reduction in Cae2+-activated [Ca2+]i signals (Fig. 10B). By contrast, [Ca2+]i signaling through endogenous muscarinic receptors was almost completely prevented by this concentration of PMA (data not shown).
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
In the present study, the CaR doublet is consistent with the expression of this protein in HEK293 cells (25, 44), and probably indicates the fusion of EGFP with the high-mannose immature form of the CaR (57). The higher molecular weight band (185 kDa) is likely the fusion of the complex carbohydrate, mature form (157 kDa) of the receptor to EGFP. The HEK-CaR.EGFP cells responded to added Cae2+ with an increase in [Ca2+]i, indicating functional expression of the receptor. Binding of Cae2+ to the extracellular domain of the receptor initiated a signal linked to the release of Ca2+ from intracellular storage sites and transient elevation of [Ca2+]i. The data reported herein indicate stimulation of the CaR in HEK-CaR.EGFP cells by 1 mM Cae2+, which varied with different clones suggesting that response to stimulation depended on the expression levels of the CaR. The plateau above basal [Ca2+]i, suggests Ca2+ influx from the extracellular medium via SOCE channels. The CaR binds Ca2+ at the extracellular domain and transduces the signal through cAMP and phospholipases (PLC, PLA2, or PLD), depending on the cell type (7). Activation of PLC leads to IP3 production and release of stored intracellular Ca2+ following activation of IP3 receptors in the endoplasmic reticulum membrane. Reduction in [Ca2+]i is rapidly achieved by Ca2+ pumps (Ca2+-ATPase) located in the endoplasmic reticulum and plasma membranes. However, the depletion of stored Ca2+ also opens plasma membrane SOCE channels, that allow influx of Ca2+ resulting in a sustained plateau (41, 42) or periodic oscillations of [Ca2+ ]i that regulate cytosolic as well as nuclear functions of the cell (3, 12). Multiple signaling mechanisms are implicated in these events; however, the molecular mechanisms of these Ca2+ signaling pathways are not clear. Although multiple mechanisms have been described for Ca2+ influx (43), the nature of the entry channels is at present not known. Recent results implicate two new important players in this process, Stim1 (31, 47) and Orai1 (15, 54).
The [Ca2+]i oscillations, observed in this study, may be related to localized fluctuations in IP3 levels within a population of cells or recruitment of regulators of G protein signaling (RGS) protein to the membrane to promote GTP binding to G
q, thus uncoupling receptor-catalyzed loading of G
q-GTP from PLC
activation in the presence of persistent agonist stimulation (48, 32, 58). Other studies have shown that stimulation of the CaR leads to [Ca2+]i oscillations, which play a key role in signal transduction by regulating Ca2+/calmodulin-dependent protein kinase II (53), PKC (36), mitochondrial metabolism (21) and nuclear transcriptional activity that results in differential gene expression (13, 24). These oscillations can be organized at the subcellular level as propagating Ca2+ waves, and serve as an important mechanism in regulating cell function. For example, parathyroid cells exhibiting [Ca2+]i oscillations have been shown to secrete less parathyroid hormone (34) and therefore may contribute to CaR-mediated inhibition of the secretion of the hormone from parathyroid glands. The present findings conform to the earlier findings, which showed that cells heterogeneously expressing the CaR undergo [Ca2+]i oscillations at low [Ca2+]e (5). The concentration-dependent increase in oscillation frequencies is interesting and the mechanism and significance of this are being explored.
An important new finding of the present study is that cumulative addition of low concentrations of Cae2+ caused rapid reduction in peak [Ca2+]i, suggesting receptor desensitization. This finding is in contrast with that described for the parathyroid CaR, which showed increase in Cai2+ mobilization following cumulative additions of Cae2+ (2, 5, 17). Gd3+ and NPS R-467, activators of the parathyroid CaR, also desensitized the CaR. Gd3+ is an activator of the parathyroid receptor, but also blocks SOCE; therefore, the reduction in response observed after the second application could be attributable to blockade of receptor-mediated Cai2+ mobilization and entry. On the other hand, the reduction in the effect of NPS R-467, an allosteric activator of the CaR, could reflect receptor uncoupling from signal transduction mechanisms leading to endoplasmic reticulum Ca2+ release. We have also observed that Cae2+ cross-desensitized carbachol responses (data not shown), indicating depletion of the Ca2+ pool. This suggests that the reduction in Cai2+ mobilization by repeated stimulation of the CaR could be due, in part, to impaired store refilling. Gama and Breitwieser (17) have reported desensitization of the parathyroid CaR by 10 mM Cae2+; however, other studies have shown that this receptor is resistant to Ca2+-induced desensitization (18). The DRG CaR expressed in HEK293 cells shows higher Cae2+ sensitivity and is desensitized by physiological concentrations of Ca2+, unlike the parathyroid CaR expressed in HEK293 cells (5, 17). This is novel and suggests that the DRG receptor is functionally different. A possible explanation for this difference in behavior is the fact that the amino acid sequence of the cytoplasmic domain of the DRG CaR is different from the parathyroid receptor (57). The DRG CaR may therefore be coupled differently to G protein and the release of stored Ca2+. The possibility that the fusion of EGFP to the CaR may have changed the properties of the receptor is unlikely in view of the fact that some GPCR-EGFP fusions appear to retain normal receptor characteristics within the fusion protein (28). Furthermore, no differences in desensitization have been observed between the full-length parathyroid receptor and its EGFP fusion protein expressed in HEK293 cells (17).
The observation that PKC inhibition or down regulation reduced Cai2+ mobilization as a result of receptor stimulation, indicates a role for PKC in the signaling process. This finding suggests that phosphorylation plays a role. GPCR signal desensitization, following repeated agonist challenge, is thought to be initiated by second messenger-activated PKC or GPCR kinase-mediated phosphorylation of specific serine/threonine residues within the third intracellular loop and/or COOH-terminal tail of the receptor (22). In the present study, PKC
was translocated to the plasma membrane upon phosphorylation at Ser-657, and this event occurred following stimulation of the CaR, indicating PKC
activation. A similar finding was previously reported by Sakwe and colleagues (51), who showed that in both parathyroid and HEK293 cells expressing exogenous human kidney CaR, exposure to 25 mM Cae2+ resulted in the translocation of cytosolic PKC to the membrane fraction and p-PKC
remained associated with the membrane fraction for at least 6 h after treatment. Other studies have shown that PKC activators, such as PMA, substantially reduce Ca2+-evoked increase in IP3 and Cai2+ levels in bovine parathyroid cells (45). This effect was attributed to PKC phosphorylation of the receptor at specific phosphorylation sites in the intracellular domains of the CaR. Surprisingly, for the CaR, we observed just the opposite: PMA had little or no effect on [Ca2+]i, whereas inhibition of PKC reduced the responses. These findings clearly indicate that PKC plays an intriguing role in the regulation of the response mediated by the CaR. The mechanism of regulation, however, is quite complex and can involve multiple targets including the receptor as well as the various signal transduction proteins and Ca2+ channels and requires a rigorous examination of the role of other PKC isoforms.
Our data suggest that reduction in the amplitude of the [Ca2+]i transient following cumulative applications of Cae2+ was due to modulation of the coupling mechanism of the receptor to signaling proteins resulting from persistent stimulation. However, PKC does not seem to be involved in mediating the desensitization. Knowledge of the underlying mechanism will require additional investigation. Nonetheless, this finding is very important since the receptor can be a useful target for drugs that can modulate [Ca2+]i. The time-dependent reduction of the CaR responsiveness to [Ca2+]e constitutes an important physiological feedback control mechanism that probably protects the receptor from overstimulation. The parathyroid CaR exhibits persistent responsiveness to Ca2+ (6, 18), a property that probably allows some level of activation at all times unlike most GPCRs, which show prominent or complete loss of activation following repeated exposure to agonist (10). The DRG CaR appears to behave as the latter, and is therefore functionally different from the parathyroid receptor.
| GRANTS |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
Present address for A. C. Howlett: Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157.
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
| REFERENCES |
|---|
|
|
|---|
2. Bai M, Trivedi S, Lane CR, Yang Y, Quinn SJ, Brown EM. Protein kinase C phosphorylation of threonine at position 888 in Ca2+o-sensing receptor (CaR) inhibits coupling to Ca2+ store release. J Biol Chem 273: 2126775, 1998.
3. Berridge MJ. Inositol trisphosphate and calcium signaling. Nature 361: 315325, 1993.[CrossRef][Medline]
4. Bikle DD, Ratnam A, Mauro T, Harris J, Pillai S. Changes in calcium responsiveness and handling during keratinocyte differentiation. Potential role of the calcium receptor. J Clin Invest 97: 10851093, 1996.[ISI][Medline]
5. Breitwieser GE, Gama L. Calcium-sensing receptor activation induces intracellular calcium oscillations. Am J Physiol Cell Physiol 280: C1412C1421, 2001.
6. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hedinger MA, Lytton J, Hebert SC. Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature 366: 575580, 1993.[CrossRef][Medline]
7. Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81: 239297, 2001.
8. Bukoski RD, Bian K, Wang Y, Mupanomunda M. Perivascular sensory nerve Ca2+ receptor and Ca2+-induced relaxation of isolated arteries. Hypertension 30: 14311439, 1997.
9. Bukoski RD, Batkai S, Jarai Z, Wang Y, Offertaler L, Jackson WF, Kunos G. CB1 receptor antagonist SR141716A inhibits Ca2+-induced relaxation in CB1 receptor-deficient mice. Hypertension 39: 251260, 2002.
10. Bunemann M, Lee KB, Pals-Rylaasdam R, Roseberry AG, Hosey MM. Desensitization of G protein-coupled receptors in the cardiovascular system. Annu Rev Physiol 61: 169192, 1999.[CrossRef][ISI][Medline]
11. Chattopadhyay N, Cheng I, Roggers K, Riccardi D, Hall A, Diaz R, Hebert SC, Soybel DI, Brown EM. Identification and localization of extracellular Ca2+-sensing receptor in rat intestine. Am J Physiol Gastrointest Liver Physiol 274: G122G130, 1998.
12. Clapham DE. Calcium signaling. Cell 80: 259268, 1995.[CrossRef][ISI][Medline]
13. Dolmetsch RE, Lewis RS, Goodnow CC, Healy JI. Differential activation of transcription factors induced by Ca2+ response amplitude and duration. Nature 386: 855858, 1997.[CrossRef][Medline]
14. Ferry S, Traiffort E, Stinnakre J, Ruat M. Developmental and adult expression of rat calcium-sensing receptor transcripts in neurons and oligodendrocytes. Eur J Neurosci 12: 872884, 2000.[CrossRef][ISI][Medline]
15. Feske S, Gwack Y, Prakriya M, Srikanth S, Puppel SH, Tanasa B, Hogan PG, Lewis RS, Daly M, Rao A. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature 441: 163165, 2006.[CrossRef][Medline]
16. Gama L, Baxendale-Cox LM, Breitwieser GE. Ca2+-sensing receptors in intestinal epithelium. Am J Physiol Cell Physiol 273: C1168C1175, 1997.
17. Gama L, Breitwieser GE. A carboxy-terminal domain controls the cooperativity for extracellular Ca2+ activation of the human calcium sensing receptor. A study with receptor-green fluorescent protein fusions. J Biol Chem 273: 2871229718, 1998.
18. Garret JE, Capuano IV, Hammerland LG, Hung BC, Brown EM, Hebert SC, Nemeth EF, Fuller F. Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs. J Biol Chem 270: 1291912925, 1995.
19. Goebel SU, Peghini PL, Goldsmith PK, Spiegel AM, Gibril E, Raffeld M, Jensen RT, Serrano J. Expression of the calcium-sensing receptor in gastrinomas. J Clin Endocrinol Metab 85: 41314137, 2000.
20. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 260: 34403450, 1985.
21. Hajnoczky G, Robb-Gaspers LD, Seitz MB, Thomas AP. Decoding of cytosolic calcium oscillations in the mitochondria. Cell 82: 415424, 1995.[CrossRef][ISI][Medline]
22. Hausdorff WP, Hnatowich M, O'Dowd BF, Caron MG, Lefkowitz RJ. A mutation of the
2-adrenergic receptor impairs agonist activation of adenlyl cyclase without affecting high affinity agonist binding. J Biol Chem 265: 13881393, 1990.
23. Hoon MA, Andler E, Lindemeier J, Batter JF, Ryba NJP, Zuker CS. Putative mammalian taste receptors: a class of taste-specific GPCRs with distinct topographic selectivity. Cell 96: 541551, 1999.[CrossRef][ISI][Medline]
24. Hu Q, Deshpande S, Irani K, Ziegelstein RC. [Ca2+]i oscillation frequency regulates agonist-stimulated NF-
B transcriptional activity. J Biol Chem 274: 3399533998, 1999.
25. Hu J, Hauache O, Spiegel AM. Human Ca2+ receptor cysteine-rich domain. Analysis of function of mutant and chimeric receptors. J Biol Chem 275: 1638216389, 2000.
26. Houamed KM, Kuijper JL, Gilbert TL, Haldeman BA, O'hara PJ, Mulvihill ER, Almers W, Hagen FS. Cloning, expression, and gene structure of G protein-coupled glutamate receptor from rat brain. Science 252: 13181321, 1991.
27. Ishioka N, Bukoski RD. A role for N-arachidonylethanolamine (Anandamide) as the mediator of sensory nerve-dependent Ca2+-induced relaxation. J Pharmacol Exp Toxicol 289: 245250, 1999.
28. Kallal L, Gagnon AW, Penn RB, Benovic JL. Visualization of agonist-induced sequestration and down-regulation of a green fluorescent protein-tagged beta2-adrenergic receptor. J Biol Chem 273: 3228, 1998.
29. Kaupmann K, Huggel K, Heid J, Flor PJ, Bischoff S, Mickel SJ, MacMaster G, Angst C, Bittiger H, Froestl W, Bettler B. Expression cloning of GABAB receptors uncovers similarity to metabotropic glutamate receptors. Nature 386: 239246, 1997.[CrossRef][Medline]
30. Kifor O, Diaz R, Butters R, Kifor I, Brown EM. The calcium-sensing receptor is localized in caveolin-rich plasma membrane domains of bovine parathyroid cells. J Biol Chem 273 : 2107821713, 1998.
31. Liou J, Kim ML, Heo WD, Jones JT, Myers JW, Ferrell JE Jr, Meyer T. STIM is a Ca2+ sensor essential for Ca2+-store-depletion-triggered Ca2+ influx. Curr Biol 15: 12351241, 2005.[CrossRef][ISI][Medline]
32. Luo H, Lindeman RP, Chase SH. Participation of protein kinase C in desensitization to bradykinin and to carbachol in MDCK cells. Am J Physiol Renal Fluid Electrolyte Physiol 262: F499F506, 1992.
33. Masu M, Tanabe Y, Tsuchida K, Shigemoto R, Nakanishi S. Sequence and expression of metabotropic glutamate receptor. Nature 349: 760765, 1991.[CrossRef][Medline]
34. Miki H, Maercklein PB, Fitzpatrick LA. Spontaneous oscillations of intracellular calcium in single bovine parathyroid cells may be associated with the inhibition of parathyroid hormone secretion. Endocrinology 136: 29542959, 1995.[Abstract]
35. Mupanomunda M, Wang Y, Bukoski RD. Effect of chronic sensory denervation on Ca2+-induced relaxation of isolated mesenteric resistance arteries. Am J Physiol Heart Circ Physiol 274: H1655H1661, 1998.
36. Oancea E, Meyer T. Protein kinase C as a molecular machine for decoding calcium and diacylglycerol signals. Cell 95: 307318, 1998.[CrossRef][ISI][Medline]
37. Oda Y, Tu CL, Pillai S, Bikle DD. The calcium sensing receptor and its alternatively spliced form in keratinocyte differentiation. J Biol Chem 273: 2334423352, 1998.
38. Ohanian J, Gatfield KM, Ward DT, Ohanian V. Evidence for a functional calcium-sensing receptor that modulates myogenic tone in rat subcutaneous small arteries. Am J Physiol Heart Circ Physiol 288: H1756H1762, 2005.
39. Pi M, Hinson TK, Quarles L. Failure to detect the extracellular calcium-sensing receptor (CasR) in human osteoblast cell lines. J Bone Miner Res 14: 13101319, 1999.[CrossRef][ISI][Medline]
40. Pi M, Faber P, Ekema G, Jackson PD, Ting A, Wang N, Fontilla-Poole M, Mays RW, Brunden KR, Harrington JJ, Quarles LD. Identification of a novel extracellular cation-sensing G-protein-coupled receptor. J Biol Chem 280: 4020140209, 2005.
41. Putney JW Jr. Capacitative calcium entry revisited. Cell Calcium 11: 611624, 1990.[CrossRef][ISI][Medline]
42. Putney JW Jr., Bird GSJ. The inositol phosphate-calcium signaling system in non-excitable cells. Endocr Rev 14: 610631, 1993.[CrossRef][ISI][Medline]
43. Putney JW Jr., Ribeiro CM. Signaling pathways between the plasma membrane and endoplasmic reticulum calcium stores. Cell Mol Life Sci 57: 12721286, 2000.[CrossRef][ISI][Medline]
44. Quitterer U, Hoffmann M, Freichel M, Lohse MJ. Paradoxical block of parathormone secretion is mediated by increased activity of G
subunits. J Biol Chem 276: 67636769, 2001.
45. Racke FK, Nemeth EF. Protein kinase C modulates hormone secretion regulated by extracellular polycations in bovine parathyroid cells. J Physiol 468: 163176, 1993.
46. Riccardi D, Park J, Lee WS, Gamba G, Brown EM. Cloning and functional expression of rat kidney extracellular calcium/polyvalent cation-sensing receptor. Proc Natl Acad Sci USA 92: 131135, 1995.
47. Roos J, DiGregorio PJ, Yeromin AV, Ohlsen K, Lioudyno M, Zhang S, Safrina O, Kozak JA, Wagner SL, Cahalan MD, Velicelebi G, Stauderman KAJ. STIM1, an essential and conserved component of store-operated Ca2+ channel function. Cell Biol 169: 381382, 2005.[CrossRef]
48. Ross EM, Wilkie TM. GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu Rev Biochem 69: 795827, 2000.[CrossRef][ISI][Medline]
49. Ruat M, Molliver ME, Snowman AM, Snyder SH. Calcium sensing receptor: molecular cloning in rat and localization to nerve terminals. Proc Natl Acad Sci USA 92: 31613165, 1995.
50. Ryba NJ, Tirindelli R. A new multigene family of putative pheromone receptors. Neuron 19: 371379, 1997.[CrossRef][ISI][Medline]
51. Sakwe AM, Larsson M, Rask L. Involvement of protein kinase C-
and -
in extracellular Ca2+ signaling mediated by the calcium sensing receptor. Exp Cell Res 297: 560573, 2004.[CrossRef][ISI][Medline]
52. Shivji F, Cheng H, Zwiers H, Hollenberg MD, Hanley DA. Identification of classical, novel, and atypical protein kinase C isoenzymes in the bovine parathyroid. Endocrinology 137: 37773783, 1996.[Abstract]
53. Soderling TR, Chang B, Brickey D. Cellular signaling through multifunctional Ca2+/calmodulin-dependent protein kinase II. J Biol Chem 276: 37193722, 2001.
54. Vig M, Peinelt C, Beck A, Koomoa DL, Rabah D, Koblan-Huberson M, Kraft S, Turner H, Fleig A, Penner R, Kinet JP. CRACM1 is a plasma membrane protein essential for store-operated Ca2+ entry. Science 312: 12201223, 2006.
55. Wang Y, Bukoski RD. Distribution of the perivascular nerve Ca2+ receptor in rat arteries. Br J Pharmacol 125: 13971404, 1998.[CrossRef][ISI][Medline]
56. Wang Y, Bukoski RD. Use of acute phenolic denervation to show the neuronal dependence of Ca2+-induced relaxation of isolated arteries. Life Sci 64: 887894, 1999.[CrossRef][ISI][Medline]
57. Wang Y, Awumey EK, Chatterjee PK, Somasundaram C, Bian K, Rogers KV, Dunn C, Bukoski RD. Molecular cloning and characterization of a rat sensory nerve Ca2+-sensing receptor. Am J Physiol Cell Physiol 285: C64C75, 2003.
58. Wang X, Huang G, Luo X, Penninger JF, Muallem S. Role of regulator of G protein signaling 2 (RGS2) in Ca2+ oscillations and adaptation of Ca2+ signaling to reduce excitability of RGS2/ cells. J Biol Chem 279: 4164241649, 2004.
This article has been cited by other articles:
![]() |
E. M. Awumey, S. K. Hill, D. I. Diz, and R. D. Bukoski Cytochrome P-450 metabolites of 2-arachidonoylglycerol play a role in Ca2+-induced relaxation of rat mesenteric arteries Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H2363 - H2370. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||